CRBU vs. JSPR, MGTX, SOPH, AVXL, TNYA, AURA, IVVD, BDTX, GLUE, and PSTX
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Jasper Therapeutics (JSPR), MeiraGTx (MGTX), SOPHiA GENETICS (SOPH), Anavex Life Sciences (AVXL), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), Invivyd (IVVD), Black Diamond Therapeutics (BDTX), Monte Rosa Therapeutics (GLUE), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
Caribou Biosciences (NASDAQ:CRBU) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Jasper Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Jasper Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 21 mentions for Jasper Therapeutics and 18 mentions for Caribou Biosciences. Jasper Therapeutics' average media sentiment score of 0.87 beat Caribou Biosciences' score of -0.06 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Caribou Biosciences has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
Jasper Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -345.05%. Caribou Biosciences' return on equity of -33.42% beat Jasper Therapeutics' return on equity.
Jasper Therapeutics received 10 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 83.87% of users gave Jasper Therapeutics an outperform vote while only 51.61% of users gave Caribou Biosciences an outperform vote.
Caribou Biosciences currently has a consensus target price of $22.50, suggesting a potential upside of 537.39%. Jasper Therapeutics has a consensus target price of $64.29, suggesting a potential upside of 178.90%. Given Caribou Biosciences' higher possible upside, equities analysts clearly believe Caribou Biosciences is more favorable than Jasper Therapeutics.
Summary
Jasper Therapeutics beats Caribou Biosciences on 9 of the 17 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
